Advertisement

Treatment of Graves’ Disease

  • Luigi Bartalena
Reference work entry
Part of the Endocrinology book series (ENDOCR)

Abstract

Treatment of hyperthyroidism due to Graves’ disease relies on the use of antithyroid drugs, radioiodine treatment, or thyroidectomy. None of these treatments are perfect, because they are not therapies targeting pathogenic mechanisms of the disease. Selection of either treatment is based on several criteria, but the choice should be shared with the informed patient. The major extrathyroidal manifestation of Graves’ disease, i.e., Graves’ orbitopathy, when moderate and active should be treated with high doses of intravenous glucocorticoids. This chapter provides an overview of treatment options for both hyperthyroidism and extrathyroidal manifestations, underscoring advantages and disadvantages of therapies, as well as preferred strategies in case of under particular circumstances, such as pregnancy and childhood.

Keywords

Graves’ hyperthyroidism Antithyroid drugs Thionamides Methimazole Propylthiouracil Radioiodine Thyroidectomy Pregnancy Childhood Subclinical hyperthyroidism Graves’ orbitopathy Thyroid dermopathy 

References

  1. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves’ hyperthyroidism. Eur J Endocrinol. 2005;153:489–98.CrossRefPubMedGoogle Scholar
  2. Angell TE, Lechner MG, Nguyen CT, Salvato VL, Nicoloff JT, LoPresti JS. Clinical features and hospital outcome in thyroid storm: a retrospective cohort study. J Clin Endocrinol Metab. 2015;100:451–9.CrossRefPubMedGoogle Scholar
  3. Barbesino G, Tomer Y. Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab. 2013;98:2247–55.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Bartalena L. The dilemma of how to manage Graves’ hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab. 2011;96:592–9.CrossRefPubMedGoogle Scholar
  5. Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol. 2013;9:724–34.CrossRefPubMedGoogle Scholar
  6. Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest. 2014;38:691–700.CrossRefGoogle Scholar
  7. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338:73–8.CrossRefPubMedGoogle Scholar
  8. Bartalena L, Krassas GE, Wiersinga WM, Marcocci C, Salvi M, Daumerie C, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97:4454–63.CrossRefPubMedGoogle Scholar
  9. Bartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F. Effects of treatment modalities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian Society of Endocrinology consensus statement. J Endocrinol Invest. 2015;38:481–7.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016a;5:9–26.CrossRefPubMedPubMedCentralGoogle Scholar
  11. Bartalena L, Burch HB, Burman HD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol (Oxf). 2016b;84:115–20.CrossRefGoogle Scholar
  12. Bartalena L, Chiovato L, Vitti P. Management of hyperthyroidism due to Graves’ disease: frequently asked questions and answers (if any). J Endocrinol Invest. 2016c;39:1105–14.CrossRefPubMedGoogle Scholar
  13. Bartalena L, Masiello E, Magri F, Veronesi G, Bianconi E, Zerbini F, et al. The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. J Endocrinol Invest. 2016d;39:1445–1451.CrossRefPubMedGoogle Scholar
  14. Biondi B, Bartalena L, Coopper DS, Hegedus L, Laurberg P, Kahaly GJ. The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J. 2015;4:149–63.CrossRefPubMedPubMedCentralGoogle Scholar
  15. Boelaert K, Maisonneuve P, Torlinska B, Franklyn JA. Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine. J Clin Endocrinol Metab. 2013;98:1869–82.CrossRefPubMedGoogle Scholar
  16. Bogazzi F, Giovannetti C, Fessehatsion R, Tanda ML, Campomori A, Compri E, et al. Impact of lithium on efficacy of radioactive iodine therapy for Graves’ disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J Clin Endocrinol Metab. 2010;95:201–8.CrossRefGoogle Scholar
  17. Bonnema SJ, Hegedus L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012;33:920–80.CrossRefPubMedGoogle Scholar
  18. Bonnema SJ, Bennedbaek FN, Gram J, Veje A, Marving J, Hegedus L. Resumption of methimazole after 131I therapy of hyperthyroid diseases: effect on thyroid function and volume evaluated by a randomized clinical trial. Eur J Endocrinol. 2003;149:485–92.CrossRefPubMedGoogle Scholar
  19. Bowman P, Osborne NJ, Sturley R, Vaidya B. Carbimazole embriopathy: implications for the choice of antithyroid drugs in pregnancy. Q J Med. 2012;105:189–93.CrossRefGoogle Scholar
  20. Brandt F, Green A, Hegedus L, Brix TH. A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol. 2011;165:491–7.CrossRefPubMedGoogle Scholar
  21. Brandt F, Thvilum M, Almind D, et al. Graves’ disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study. Thyroid. 2013a;23:408–13.CrossRefPubMedGoogle Scholar
  22. Brandt F, Thvilum M, Almind D, et al. Morbidity before and after the diagnosis of hyperthyroidsm: a nationwide register-based study. PLoS One. 2013b;8:e66711.PubMedPubMedCentralCrossRefGoogle Scholar
  23. Brito JP, Castaneda-Guarderas A, Gionfriddo NR, Singh Ospina N, Maraka S, Dean DS, et al. Development and pilot testing of an encounter tool for shared decision making about the treatment of Graves’ disease. Thyroid. 2015;25:1191–8.CrossRefPubMedPubMedCentralGoogle Scholar
  24. Brito JP, Stephanie S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham R, et al. Antithyroid drugs – the most common treatment for Graves’ disease in the United states: a nationwide population-based study. Thyroid. 2016;26:1144–5.CrossRefPubMedGoogle Scholar
  25. Burch HB, Cooper DS. Management of Graves disease. A review. JAMA. 2015;314:2544–54.CrossRefPubMedGoogle Scholar
  26. Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012;97:4549–58.CrossRefPubMedGoogle Scholar
  27. Ceccarelli C, Canale D, Battisti P, Cagliaresi C, Moscatelli A, Gavioli S, et al. Testicular function after 131I therapy for hyperthyroidism. Clin Endocrinol (Oxf). 2006;65:446–52.CrossRefGoogle Scholar
  28. Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352:905–17.CrossRefPubMedGoogle Scholar
  29. Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab. 2009;94:1881–2.CrossRefPubMedGoogle Scholar
  30. De Leo S, Braverman LE. Hyperthyroidism. Lancet. 2016;338:906–18.CrossRefGoogle Scholar
  31. DeGroot L, Abalovich M, Alexander EK, Amino N, Barbour L, Cobin RH, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2543–65.CrossRefGoogle Scholar
  32. Eckstein AK, Plicht M, Lax H, Neuhäuser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG. Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91:3464–70.CrossRefPubMedGoogle Scholar
  33. Emiliano AB, Governale L, Parks M, Cooper DS. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab. 2010;95:2227–33.CrossRefPubMedPubMedCentralGoogle Scholar
  34. Erbil Y, Giriş M, Salmaslioglu A, Ozluk Y, Barbaros U, Yanik BT, Kapran Y, Abbasoglu SD, Ozarmagan S. The effect of anti-thyroid drug treatment duration on thyroid gland microvessel density and intraoperative blood loss in patients with Graves’ disease. Surgery. 2008;143:216–25.CrossRefPubMedGoogle Scholar
  35. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med. 1998;338:712–8.CrossRefPubMedGoogle Scholar
  36. Fukata S, Kuma K, Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. Thyroid. 1999;9:29–31.CrossRefPubMedGoogle Scholar
  37. Genovese BM, Noureldine SI, Gleeson EM, Tufano RP, Kandil E. What is the best definitive treatment for Graves’ disease? A systematic review of the existing literature. Am Surg Oncol. 2013;20:660–7.CrossRefGoogle Scholar
  38. Gianetti E, Russo L, Orlandi F, Chiovato L, Giusti M, Benvenga S, et al. Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy. J Endocrinol Invest. 2015;38:977–85.CrossRefPubMedGoogle Scholar
  39. Guo Z, Yu P, Liu Z, Si Y, Jin M. Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves’ disease: a meta-analysis of randomized clinical trials. Clin Endocrinol (Oxf). 2013;79:739–46.Google Scholar
  40. Havgaard Kjaer R, Smedegard Hansen M, Hansen D. Increasing incidence of juvenile thyrotoxicosis in Denmark: a nationwide study, 1998–2012. Horm Res Paediatr. 2015;84:102–7.CrossRefPubMedGoogle Scholar
  41. Hegedus L, Smith TJ, Douglas RS, Nielsen CH. Targeted biological therapies for Graves’ disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab. Clin Endocrinol (Oxf); 2011;74:1–8.CrossRefGoogle Scholar
  42. Hieu TT, Russell AW, Cuneo R, Clark J, Kron T, Hall P, et al. Cancer risk after medical exposure to radioactive iodine in benign thyroid disease: a meta-analysis. Endocr Relat Cancer. 2012;19:645–55.CrossRefPubMedGoogle Scholar
  43. In H, Pearce EN, Wong AK, Burgess JF, McAneny DB, Rosen JE. Treatment options for Graves’ disease: a cost-effectiveness analysis. J Am Coll Surg. 2009;209:170–9.CrossRefPubMedGoogle Scholar
  44. Kahaly G, Schrezenmeir J, Krause U, Schweikert B, Meuer S, Muller W, et al. Ciclosporin and prednisone vs. prednisone in treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest. 1986;16:415–22.CrossRefPubMedGoogle Scholar
  45. Kahaly GJ, Rosler HP, Pitz S, Hommel G. Low- versus high-dose orbital radiotherapy for Graves’ ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab. 2000;85:102–8.PubMedGoogle Scholar
  46. Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2005;90:5234–40.CrossRefPubMedGoogle Scholar
  47. Kim HJ, Kim BH, Yan JS, et al. The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single-center retrospective study. Am J Gastroenterol. 2001;96:165–9.CrossRefPubMedGoogle Scholar
  48. Korelitz JJ, McNally DL, Masters MN, Li SX, Xu Y, Rivkees SA. Prevalence of thyrotoxicosis, antithyroid drug use and neonatal outcomes with an integrated healthcare delivery system. Thyroid. 2013;23:758–65.CrossRefPubMedPubMedCentralGoogle Scholar
  49. La Cour JL, Jensen LT, Vej-Hansen A, Nygaard B. Radioiodine therapy increases the risk of cerebrovascular events in hyperthyroid and euthyroid patients. Eur J Endocrinol. 2015;172:771–8.CrossRefPubMedGoogle Scholar
  50. Lazarus JH, Bartalena L, Marcocci C, Kahaly GJ, Krassas G, Wiersinga WM. Glucocorticoid administration for Graves’ hyperthyroidism treated by radioiodine. A questionnaire survey among members of the European Thyroid Association. J Endocrinol Invest. 2010;33:409–13.CrossRefPubMedGoogle Scholar
  51. Le Moli R, Baldeschi L, Saeed P, Regensburg N, Mourits MP, Wiersinga WM. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves’ ophthalmopathy. Thyroid. 2007;17:357–62.CrossRefPubMedGoogle Scholar
  52. Linding Andersen S, Olsen J, Wu CS, Laurberg P. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab. 2013;98:4373–81.CrossRefGoogle Scholar
  53. Linding Andersen S, Olsen J, Wu CS, Laurberg P. Severity of birth defects after propylthiouracil exposure in early pregnancy. Thyroid. 2014;10:1533–40.CrossRefGoogle Scholar
  54. Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell’Unto E, Rocchi R, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: results of a prospective. single-blind, randomized study. J Clin Endocrinol Metab. 2001;86:3562–7.PubMedGoogle Scholar
  55. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, et al. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med. 2011;364:1920–32.CrossRefPubMedGoogle Scholar
  56. Marcocci C, Watt T, Altea MA, Rasmussen AK, Feldt-Rasmussen, Orgiazzi J, et al. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves’ orbitopathy: a questionnaire survey among members of the European Thyroid Association. Eur J Endocrinol. 2012;166:247–53.CrossRefPubMedGoogle Scholar
  57. Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab. 2007;92:2190–6.CrossRefPubMedGoogle Scholar
  58. Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2005;90:5321–3.CrossRefPubMedGoogle Scholar
  59. Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L. Prevalence and natural history of Graves’ orbitopathy in the XXI century. J Endocrinol Invest. 2013;36:444–9.Google Scholar
  60. Piantanida E, Lai A, Sassi L, Gallo D, Spreafico M, Tanda ML, Bartalena L. Outcome prediction of treatment of Graves’ hyperthyroidism with antithyroid drugs. Horm Metab Res. 2015;47:767–72.CrossRefPubMedGoogle Scholar
  61. Prummel MF, Mourits MP, Berghout A, Krenning EP, van der Gaag R, Koornneef L, et al. Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N Engl J Med. 1989;321:1353–9.CrossRefPubMedGoogle Scholar
  62. Riedl M, Kolbe E, Kampmann E, Kramer I, Kahaly GJ. Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves’ orbitopathy. J Endocrinol Invest. 2015;38:177–82.CrossRefPubMedGoogle Scholar
  63. Rivkees SA. Controversies in the management of Graves’ disease in children. J Endocrinol Invest. 2016;39:1247–57.CrossRefPubMedGoogle Scholar
  64. Rivkees SA, Szarfman A. Dissimilar hepatoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab. 2010;95:3260–7.CrossRefPubMedGoogle Scholar
  65. Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med. 2011;364:542–50.CrossRefPubMedGoogle Scholar
  66. Ross DS, Burch HB, Copper DS, Greenlee MC, Laurberg P, Maia AL, et al. American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicisos. Thyroid. 2016;26:1343–421.CrossRefPubMedGoogle Scholar
  67. Ruiz JK, Rossi GV, Vallejos HA, Brener RW, Lopez IB, Escribano AA. Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother. 2003;37:224–8.CrossRefPubMedGoogle Scholar
  68. Ryodi E, Metso S, Jaatinen P, Huhtala H, Saaristo R, Valimaki M, et al. Cancer incidence and mortality in patients treated either with RAI or thyroidectomy for hyperthyroidism. J Clin Endocrinol Metab. 2015;100:3710–7.CrossRefPubMedGoogle Scholar
  69. Salvi M, Vannucchi G, Beck-Peccoz P. Potential utility of rituximab for Graves’ orbitopathy. J Clin Endocrinol Metab. 2013;98:4291–9.CrossRefPubMedGoogle Scholar
  70. Salvi M, Vannucchi G, Currò N, Campi I, Covelli D, Dazzi D, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100:422–31.CrossRefPubMedGoogle Scholar
  71. Sawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW, Brierley JD, et al. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf). 2008;69:479–90.CrossRefPubMedGoogle Scholar
  72. Shiber S, Stiebel-Kalish H, Shimon I, Grossman A, Robenshtok E. Glucocorticoid regimens for prevention of Graves’ ophthalmopathy progression following radioiodine treatment: systematic review and meta-analysis. Thyroid. 2014;24:1515–23.CrossRefPubMedGoogle Scholar
  73. Sisson JC, Freitas J, McDougall IR, Dauer LT, Hurley JR, Brierley JD, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid. 2011;21:335–46.CrossRefPubMedGoogle Scholar
  74. Sisti E, Coco B, Menconi F, Leo M, Rocchi R, Latrofa F, et al. Intravenous glucocorticoid therapy for Graves’ ophthalmopathy and acute liver damage: an epidemiological study. Eur J Endocrinol. 2015a;172:269–76.CrossRefPubMedGoogle Scholar
  75. Sisti E, Menconi F, Leo M, Profilo MA, Mautone T, Mazzi B, et al. Long-term outcome of Graves’ orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy. J Endocrinol Invest. 2015b;38:661–8.CrossRefPubMedGoogle Scholar
  76. Smith TJ, Hegedus L. Graves’ disease. N Engl J Med. 2016;375:1552–65.CrossRefPubMedGoogle Scholar
  77. Sosa IA, Tuggle CT, Wabg TS, Thomas DC, Boudourakis L, Rivkees S, et al. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab. 2008;93:3058–65.CrossRefPubMedGoogle Scholar
  78. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011;21:1081–125.CrossRefPubMedPubMedCentralGoogle Scholar
  79. Stan M, Salvi M. Rituximab therapy for Graves’ orbitopathy. Lessons from randomized clinical trials. Eur J Endocrinol. 2017;176:R101–9.Google Scholar
  80. Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab. 2015;100:432–41.CrossRefPubMedGoogle Scholar
  81. Stiggelbout AM, Van der Weijden T, De Wit MPT, Frosch D, Légare F, Montori V, et al. Shared decision making: really putting patients at the centre of healthcare. Br Med J. 2012;344:e256.CrossRefGoogle Scholar
  82. Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, et al. Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2013;98:3671–7.CrossRefPubMedPubMedCentralGoogle Scholar
  83. Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment? Eur J Endocrinol. 1994;130:494–7.CrossRefPubMedGoogle Scholar
  84. Tanda ML, Bartalena L. Efficacy and safety of orbital radiotherapy for Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97:3857–65.CrossRefPubMedGoogle Scholar
  85. Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, et al. Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013;98:1443–9.CrossRefPubMedGoogle Scholar
  86. Ting HH, Brito JP, Montori VM. Shared decision making. Science and action. Circ Cardiovasc Qual Outcomes. 2014;7:323–7.CrossRefPubMedGoogle Scholar
  87. Törring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine – a prospective, randomized study. J Clin Endocrinol Metab. 1996;81:2986–93.PubMedGoogle Scholar
  88. Träisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, et al. Thyroid associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab. 2009;94:3700–7.CrossRefPubMedGoogle Scholar
  89. Tun NN, Beckett G, Zammitt NN, Strachan MW, Seckl JR, Gibb FW. Thyrotropin receptor antibody levels at diagnosis and after thionamide course predict Graves’ disease relapse. Thyroid. 2016;26:1004–9.CrossRefPubMedGoogle Scholar
  90. Vaidya B, Williams GR, Abraham P, Pearce SH. Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin Endocrinol (Oxf). 2008;68:814–20.CrossRefGoogle Scholar
  91. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, et al. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7:369–75.CrossRefPubMedGoogle Scholar
  92. Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. Br J Clin Pharmacol. 2014;78:619–29.CrossRefPubMedPubMedCentralGoogle Scholar
  93. Watanabe N, Narimatsu H, Yoshimura Noh J, Yamaguchi T, Kobayashi K, Kami M, et al. Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50, 385 patients with Graves’ disease. J Clin Endocrinol Metab. 2012;97:E49–53.CrossRefPubMedGoogle Scholar
  94. Weetman AP. Graves’ disease following immune reconstitution of immunomodulatory treatment: should we manage it any differently? Clin Endocrinol (Oxf). 2014;80:629–32.CrossRefGoogle Scholar
  95. Wiersinga W. Advances in treatment of active, moderate-to-severe Graves’ ophthalmopathy. Lancet Diabetes Endocrinol. 2016; doi:10.1016/S2213-8587(16)30046-8 (e-pub ahead of print).Google Scholar
  96. Yang J, Li LF, Xu Q, Zhang J, Weng W-W, Zhu YI, et al. Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China. Thyroid. 2015;25:278–83.CrossRefPubMedGoogle Scholar
  97. Yang J, Zhu Y-J, Zhong JJ, Zhang J, Weng W-W, Z-f L, et al. Characteristics of drug-induced agranulocytosis in patients with hyperthyroidism: a retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years. Thyroid. 2016;26:627–33.CrossRefPubMedGoogle Scholar
  98. Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Seiya K, et al. Treatment of Graves’ disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012;97:2396–403.CrossRefPubMedGoogle Scholar
  99. Zang S, Ponto KA, Kahaly GJ. Clinical Review: intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96:320–32.CrossRefPubMedGoogle Scholar
  100. Zhyzhneuskaya S, Addison C, Tsatlidis V, Weaver JU, Razvi S. The natural history of subclinical hyperthyroidism in Graves’ disease: the rule of thirds. Thyroid. 2016;26:765–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Medicine and SurgeryUniversity of Insubria, Endocrine Unit, ASST dei Sette Laghi, Ospedale di CircoloVareseItaly

Personalised recommendations